Twist Bioscience Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2023 Annual Meeting of Stockholders held on February 7, 2023. Twist Bioscience Corporation (TWST) is incorporated in Delaware and trades on The Nasdaq Global Select Market. The company is classified as an emerging growth company.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders representing approximately 91.92% of eligible shares (52,068,575 shares) voted on three proposals:
- Proposal One (Election of Directors): Stockholders approved the election of two Class II Directors.
- Keith Crandell: 33,891,453 votes For; 13,264,841 votes Withheld; 4,912,281 Broker Non-Votes.
- Jan Johannessen: 32,240,144 votes For; 14,916,150 votes Withheld; 4,912,281 Broker Non-Votes.
- Proposal Two (Say-on-Pay): Stockholders approved the non-binding advisory resolution on Named Executive Officer compensation.
- Results: 43,379,295 votes For; 3,746,996 votes Against; 30,003 Abstentions; 4,912,281 Broker Non-Votes.
- Proposal Three (Auditor Ratification): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered accounting firm for the fiscal year ending September 30, 2023.
- Results: 52,003,570 votes For; 17,623 votes Against; 47,382 Abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the final composition of the Board of Directors following the election of Keith Crandell and Jan Johannessen.
- Confirm the level of shareholder support for executive compensation, noting that approximately 8.7% of votes cast were against the proposal.
- Review the full proxy statement for details on the specific compensation packages approved under Proposal Two.
- Check subsequent filings for the company's financial performance for the fiscal year ending September 30, 2023, as this 8-K contains no financial data.